Clinical Trial Update: Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating the combination of nivolumab and relatlimab for cutaneous squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Melanoma Institute Australia | Conditions: Cutaneous Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING